Cargando…
Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease
Intestinal fibrosis and stricture formation is an aggressive complication of Crohns disease (CD), linked to increased morbidity and costs. The present study investigates the contribution of Wingless-Int-1 (Wnt) signalling to intestinal fibrogenesis, considers potential cross-talk between Wnt and tra...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583737/ https://www.ncbi.nlm.nih.gov/pubmed/36156078 http://dx.doi.org/10.1042/CS20210889 |
_version_ | 1784813133709180928 |
---|---|
author | Lewis, Amy Sánchez, Saray Berti, Giulio Pan-Castillo, Belen Nijhuis, Anke Mehta, Shameer Eleid, Liliane Gordon, Hannah Gadhok, Radha Kimberley, Christopher Minicozzi, Annamaria Chin-Aleong, Joanne Feakins, Roger Kypta, Robert Lindsay, James Oliver Silver, Andrew |
author_facet | Lewis, Amy Sánchez, Saray Berti, Giulio Pan-Castillo, Belen Nijhuis, Anke Mehta, Shameer Eleid, Liliane Gordon, Hannah Gadhok, Radha Kimberley, Christopher Minicozzi, Annamaria Chin-Aleong, Joanne Feakins, Roger Kypta, Robert Lindsay, James Oliver Silver, Andrew |
author_sort | Lewis, Amy |
collection | PubMed |
description | Intestinal fibrosis and stricture formation is an aggressive complication of Crohns disease (CD), linked to increased morbidity and costs. The present study investigates the contribution of Wingless-Int-1 (Wnt) signalling to intestinal fibrogenesis, considers potential cross-talk between Wnt and transforming growth factor β1 (TGFβ) signalling pathways, and assesses the therapeutic potential of small-molecule Wnt inhibitors. β-catenin expression was explored by immunohistochemistry (IHC) in formalin-fixed paraffin embedded (FFPE) tissue from patient-matched nonstrictured (NSCD) and strictured (SCD) intestine (n=6 pairs). Functional interactions between Wnt activation, TGFβ signalling, and type I collagen (Collagen-I) expression were explored in CCD-18Co cells and primary CD myofibroblast cultures established from surgical resection specimens (n=16) using small-molecule Wnt inhibitors and molecular techniques, including siRNA-mediated gene knockdown, immunofluorescence (IF), Wnt gene expression arrays, and western blotting. Fibrotic SCD tissue was marked by an increase in β-catenin-positive cells. In vitro, activation of Wnt-β-catenin signalling increased Collagen-I expression in CCD-18Co cells. Conversely, ICG-001, an inhibitor of β-catenin signalling, reduced Collagen-I expression in cell lines and primary CD myofibroblasts. TGFβ increased β-catenin protein levels but did not activate canonical Wnt signalling. Rather, TGFβ up-regulated WNT5B, a noncanonical Wnt ligand, and the Wnt receptor FZD8, which contributed directly to the up-regulation of Collagen-I through a β-catenin-independent mechanism. Treatment of CCD-18Co fibroblasts and patient-derived myofibroblasts with the FZD8 inhibitor 3235-0367 reduced extracellular matrix (ECM) expression. Our data highlight small-molecule Wnt inhibitors of both canonical and noncanonical Wnt signalling, as potential antifibrotic drugs to treat SCD intestinal fibrosis. They also highlight the importance of the cross-talk between Wnt and TGFβ signalling pathways in CD intestinal fibrosis. |
format | Online Article Text |
id | pubmed-9583737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95837372022-10-27 Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease Lewis, Amy Sánchez, Saray Berti, Giulio Pan-Castillo, Belen Nijhuis, Anke Mehta, Shameer Eleid, Liliane Gordon, Hannah Gadhok, Radha Kimberley, Christopher Minicozzi, Annamaria Chin-Aleong, Joanne Feakins, Roger Kypta, Robert Lindsay, James Oliver Silver, Andrew Clin Sci (Lond) Pharmacology & Toxicology Intestinal fibrosis and stricture formation is an aggressive complication of Crohns disease (CD), linked to increased morbidity and costs. The present study investigates the contribution of Wingless-Int-1 (Wnt) signalling to intestinal fibrogenesis, considers potential cross-talk between Wnt and transforming growth factor β1 (TGFβ) signalling pathways, and assesses the therapeutic potential of small-molecule Wnt inhibitors. β-catenin expression was explored by immunohistochemistry (IHC) in formalin-fixed paraffin embedded (FFPE) tissue from patient-matched nonstrictured (NSCD) and strictured (SCD) intestine (n=6 pairs). Functional interactions between Wnt activation, TGFβ signalling, and type I collagen (Collagen-I) expression were explored in CCD-18Co cells and primary CD myofibroblast cultures established from surgical resection specimens (n=16) using small-molecule Wnt inhibitors and molecular techniques, including siRNA-mediated gene knockdown, immunofluorescence (IF), Wnt gene expression arrays, and western blotting. Fibrotic SCD tissue was marked by an increase in β-catenin-positive cells. In vitro, activation of Wnt-β-catenin signalling increased Collagen-I expression in CCD-18Co cells. Conversely, ICG-001, an inhibitor of β-catenin signalling, reduced Collagen-I expression in cell lines and primary CD myofibroblasts. TGFβ increased β-catenin protein levels but did not activate canonical Wnt signalling. Rather, TGFβ up-regulated WNT5B, a noncanonical Wnt ligand, and the Wnt receptor FZD8, which contributed directly to the up-regulation of Collagen-I through a β-catenin-independent mechanism. Treatment of CCD-18Co fibroblasts and patient-derived myofibroblasts with the FZD8 inhibitor 3235-0367 reduced extracellular matrix (ECM) expression. Our data highlight small-molecule Wnt inhibitors of both canonical and noncanonical Wnt signalling, as potential antifibrotic drugs to treat SCD intestinal fibrosis. They also highlight the importance of the cross-talk between Wnt and TGFβ signalling pathways in CD intestinal fibrosis. Portland Press Ltd. 2022-10 2022-10-14 /pmc/articles/PMC9583737/ /pubmed/36156078 http://dx.doi.org/10.1042/CS20210889 Text en © 2022 The Author(s). https://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Pharmacology & Toxicology Lewis, Amy Sánchez, Saray Berti, Giulio Pan-Castillo, Belen Nijhuis, Anke Mehta, Shameer Eleid, Liliane Gordon, Hannah Gadhok, Radha Kimberley, Christopher Minicozzi, Annamaria Chin-Aleong, Joanne Feakins, Roger Kypta, Robert Lindsay, James Oliver Silver, Andrew Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease |
title | Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease |
title_full | Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease |
title_fullStr | Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease |
title_full_unstemmed | Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease |
title_short | Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease |
title_sort | small-molecule wnt inhibitors are a potential novel therapy for intestinal fibrosis in crohns disease |
topic | Pharmacology & Toxicology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583737/ https://www.ncbi.nlm.nih.gov/pubmed/36156078 http://dx.doi.org/10.1042/CS20210889 |
work_keys_str_mv | AT lewisamy smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT sanchezsaray smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT bertigiulio smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT pancastillobelen smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT nijhuisanke smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT mehtashameer smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT eleidliliane smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT gordonhannah smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT gadhokradha smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT kimberleychristopher smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT minicozziannamaria smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT chinaleongjoanne smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT feakinsroger smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT kyptarobert smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT lindsayjamesoliver smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease AT silverandrew smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease |